Selected research
Industry Research
Pravastatin Industry Research Report 2026
Market perspective
The global Pravastatin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pravastatin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pravastatin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pravastatin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pravastatin include TEVA, Shanghai Shyndec Pharmaceutical, SANDOZ, Mylan, Jiangxi Boyaseehot Pharmaceutical, North China Pharmaceutical Group, Zydus Pharmaceuticals, Upsher-Smith Laboratories and Lupin Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pravastatin market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pravastatin Market by Company
TEVA
Shanghai Shyndec Pharmaceutical
SANDOZ
Mylan
Jiangxi Boyaseehot Pharmaceutical
North China Pharmaceutical Group
Zydus Pharmaceuticals
Upsher-Smith Laboratories
Lupin Pharmaceuticals
Hisun
Glenmark
Dr. Reddy's Laboratories
Daiichi Sankyo
Cipla Inc.
Bristol-Myers Squibb
Aurobindo Pharma
APOTEX
Accord Healthcare
Pravastatin Segment by Type
10mg Tablet
20mg Tablet
40mg Tablet
80mg Tablet
Pravastatin Segment by Application
Adults
Children
Pravastatin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pravastatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pravastatin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pravastatin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pravastatin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pravastatin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pravastatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 10mg Tablet
- 20mg Tablet
- 40mg Tablet
- 80mg Tablet
Applications
- Adults
- Children
Companies covered
- TEVA
- Shanghai Shyndec Pharmaceutical
- SANDOZ
- Mylan
- Jiangxi Boyaseehot Pharmaceutical
- North China Pharmaceutical Group
- Zydus Pharmaceuticals
- Upsher-Smith Laboratories
- Lupin Pharmaceuticals
- Hisun
- Glenmark
- Dr. Reddy's Laboratories
- Daiichi Sankyo
- Cipla Inc.
- Bristol-Myers Squibb
- Aurobindo Pharma
- APOTEX
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pravastatin Market Size (2021-2032)
- 2.2.2 Global Pravastatin Sales (2021-2032)
- 2.2.3 Global Pravastatin Market Average Price (2021-2032)
- 2.3 Pravastatin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 10mg Tablet
- 2.3.3 20mg Tablet
- 2.3.4 40mg Tablet
- 2.3.5 80mg Tablet
- 2.4 Pravastatin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pravastatin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pravastatin Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Pravastatin Revenue of Manufacturers (2021-2026)
- 3.4 Global Pravastatin Average Price by Manufacturers (2021-2026)
- 3.5 Global Pravastatin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pravastatin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pravastatin, Product Type & Application
- 3.8 Global Manufacturers of Pravastatin, Established Date
- 3.9 Global Pravastatin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 TEVA
- 4.1.1 TEVA Company Information
- 4.1.2 TEVA Business Overview
- 4.1.3 TEVA Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 TEVA Pravastatin Product Portfolio
- 4.1.5 TEVA Recent Developments
- 4.2 Shanghai Shyndec Pharmaceutical
- 4.2.1 Shanghai Shyndec Pharmaceutical Company Information
- 4.2.2 Shanghai Shyndec Pharmaceutical Business Overview
- 4.2.3 Shanghai Shyndec Pharmaceutical Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Shyndec Pharmaceutical Pravastatin Product Portfolio
- 4.2.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 4.3 SANDOZ
- 4.3.1 SANDOZ Company Information
- 4.3.2 SANDOZ Business Overview
- 4.3.3 SANDOZ Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 SANDOZ Pravastatin Product Portfolio
- 4.3.5 SANDOZ Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Pravastatin Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Jiangxi Boyaseehot Pharmaceutical
- 4.5.1 Jiangxi Boyaseehot Pharmaceutical Company Information
- 4.5.2 Jiangxi Boyaseehot Pharmaceutical Business Overview
- 4.5.3 Jiangxi Boyaseehot Pharmaceutical Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiangxi Boyaseehot Pharmaceutical Pravastatin Product Portfolio
- 4.5.5 Jiangxi Boyaseehot Pharmaceutical Recent Developments
- 4.6 North China Pharmaceutical Group
- 4.6.1 North China Pharmaceutical Group Company Information
- 4.6.2 North China Pharmaceutical Group Business Overview
- 4.6.3 North China Pharmaceutical Group Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 North China Pharmaceutical Group Pravastatin Product Portfolio
- 4.6.5 North China Pharmaceutical Group Recent Developments
- 4.7 Zydus Pharmaceuticals
- 4.7.1 Zydus Pharmaceuticals Company Information
- 4.7.2 Zydus Pharmaceuticals Business Overview
- 4.7.3 Zydus Pharmaceuticals Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zydus Pharmaceuticals Pravastatin Product Portfolio
- 4.7.5 Zydus Pharmaceuticals Recent Developments
- 4.8 Upsher-Smith Laboratories
- 4.8.1 Upsher-Smith Laboratories Company Information
- 4.8.2 Upsher-Smith Laboratories Business Overview
- 4.8.3 Upsher-Smith Laboratories Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Upsher-Smith Laboratories Pravastatin Product Portfolio
- 4.8.5 Upsher-Smith Laboratories Recent Developments
- 4.9 Lupin Pharmaceuticals
- 4.9.1 Lupin Pharmaceuticals Company Information
- 4.9.2 Lupin Pharmaceuticals Business Overview
- 4.9.3 Lupin Pharmaceuticals Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lupin Pharmaceuticals Pravastatin Product Portfolio
- 4.9.5 Lupin Pharmaceuticals Recent Developments
- 4.10 Hisun
- 4.10.1 Hisun Company Information
- 4.10.2 Hisun Business Overview
- 4.10.3 Hisun Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hisun Pravastatin Product Portfolio
- 4.10.5 Hisun Recent Developments
- 4.11 Glenmark
- 4.11.1 Glenmark Company Information
- 4.11.2 Glenmark Business Overview
- 4.11.3 Glenmark Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Glenmark Pravastatin Product Portfolio
- 4.11.5 Glenmark Recent Developments
- 4.12 Dr. Reddy's Laboratories
- 4.12.1 Dr. Reddy's Laboratories Company Information
- 4.12.2 Dr. Reddy's Laboratories Business Overview
- 4.12.3 Dr. Reddy's Laboratories Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Dr. Reddy's Laboratories Pravastatin Product Portfolio
- 4.12.5 Dr. Reddy's Laboratories Recent Developments
- 4.13 Daiichi Sankyo
- 4.13.1 Daiichi Sankyo Company Information
- 4.13.2 Daiichi Sankyo Business Overview
- 4.13.3 Daiichi Sankyo Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Daiichi Sankyo Pravastatin Product Portfolio
- 4.13.5 Daiichi Sankyo Recent Developments
- 4.14 Cipla Inc.
- 4.14.1 Cipla Inc. Company Information
- 4.14.2 Cipla Inc. Business Overview
- 4.14.3 Cipla Inc. Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Cipla Inc. Pravastatin Product Portfolio
- 4.14.5 Cipla Inc. Recent Developments
- 4.15 Bristol-Myers Squibb
- 4.15.1 Bristol-Myers Squibb Company Information
- 4.15.2 Bristol-Myers Squibb Business Overview
- 4.15.3 Bristol-Myers Squibb Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Bristol-Myers Squibb Pravastatin Product Portfolio
- 4.15.5 Bristol-Myers Squibb Recent Developments
- 4.16 Aurobindo Pharma
- 4.16.1 Aurobindo Pharma Company Information
- 4.16.2 Aurobindo Pharma Business Overview
- 4.16.3 Aurobindo Pharma Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Aurobindo Pharma Pravastatin Product Portfolio
- 4.16.5 Aurobindo Pharma Recent Developments
- 4.17 APOTEX
- 4.17.1 APOTEX Company Information
- 4.17.2 APOTEX Business Overview
- 4.17.3 APOTEX Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 APOTEX Pravastatin Product Portfolio
- 4.17.5 APOTEX Recent Developments
- 4.18 Accord Healthcare
- 4.18.1 Accord Healthcare Company Information
- 4.18.2 Accord Healthcare Business Overview
- 4.18.3 Accord Healthcare Pravastatin Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Accord Healthcare Pravastatin Product Portfolio
- 4.18.5 Accord Healthcare Recent Developments
5 Global Pravastatin Market Scenario by Region
- 5.1 Global Pravastatin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pravastatin Sales by Region: 2021-2032
- 5.2.1 Global Pravastatin Sales by Region: 2021-2026
- 5.2.2 Global Pravastatin Sales by Region: 2027-2032
- 5.3 Global Pravastatin Revenue by Region: 2021-2032
- 5.3.1 Global Pravastatin Revenue by Region: 2021-2026
- 5.3.2 Global Pravastatin Revenue by Region: 2027-2032
- 5.4 North America Pravastatin Market Facts & Figures by Country
- 5.4.1 North America Pravastatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pravastatin Sales by Country (2021-2032)
- 5.4.3 North America Pravastatin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Pravastatin Market Facts & Figures by Country
- 5.5.1 Europe Pravastatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pravastatin Sales by Country (2021-2032)
- 5.5.3 Europe Pravastatin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Pravastatin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pravastatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pravastatin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pravastatin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pravastatin Market Facts & Figures by Country
- 5.7.1 South America Pravastatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pravastatin Sales by Country (2021-2032)
- 5.7.3 South America Pravastatin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Pravastatin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pravastatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pravastatin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pravastatin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Pravastatin Sales by Type (2021-2032)
- 6.1.1 Global Pravastatin Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Pravastatin Sales Market Share by Type (2021-2032)
- 6.2 Global Pravastatin Revenue by Type (2021-2032)
- 6.2.1 Global Pravastatin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pravastatin Revenue Market Share by Type (2021-2032)
- 6.3 Global Pravastatin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pravastatin Sales by Application (2021-2032)
- 7.1.1 Global Pravastatin Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Pravastatin Sales Market Share by Application (2021-2032)
- 7.2 Global Pravastatin Revenue by Application (2021-2032)
- 7.2.1 Global Pravastatin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pravastatin Revenue Market Share by Application (2021-2032)
- 7.3 Global Pravastatin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pravastatin Value Chain Analysis
- 8.1.1 Pravastatin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pravastatin Production Mode & Process
- 8.2 Pravastatin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pravastatin Distributors
- 8.2.3 Pravastatin Customers
9 Global Pravastatin Analyzing Market Dynamics
- 9.1 Pravastatin Industry Trends
- 9.2 Pravastatin Industry Drivers
- 9.3 Pravastatin Industry Opportunities and Challenges
- 9.4 Pravastatin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst